Trials / Completed
CompletedNCT00894374
Bioequivalence Study Comparing Artesunate Tablet To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects
A Single-Dose Bioequivalence Study Comparing Artesunate Tablet (Pfizer) To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 21 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The study will determine if artesunate tablet (Pfizer), an antimalarial agent, is pharmaceutically equivalent to Arsuamoon® tablets (Guilin-China).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Artesunate (Test) | Oral tablet, single dose, 1 x 100 mg |
| DRUG | Artesunate (Comparator) | Oral tablet, single dose, 2 x 50 mg |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2009-08-01
- Completion
- 2009-08-01
- First posted
- 2009-05-07
- Last updated
- 2010-06-25
Locations
1 site across 1 country: Singapore
Source: ClinicalTrials.gov record NCT00894374. Inclusion in this directory is not an endorsement.